Atazanavir

DB01072ApprovedInvestigationalSmall moleculeHIV Protease Inhibitors Protease Inhibitors

Atazanavir is an antiviral protease inhibitor used in combination with other antiretrovirals for the treatment of HIV. Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class.

Mechanism: Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2.
Curator reviewed · 1 reference
Primary indication: Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg.Curator reviewed · 3 structured indications
Formula / weight: C₃₈H₅₂N₆O₇ · 704.8555 g/mol (avg)
First approval: Canada, 2003 · United States, 2003 · European Union, 2016
Code names: BMS-232632 · CGP-73547
Brand names: Atazanavir Mylan
Evotaz
Reyataz

Resolves to

Compound

UNIIQZU4H47A3SCAS198904-31-3ChEMBLCHEMBL1163ChEBI37924PubChem148192KEGGD07471

Clinical / RWD

RxNorm343047ATCJ05AE08ATCJ05AR15ATCJ05AR23PharmGKBPA10251

Structure

InChIKeyAXRYRYVKAWYZBR-GASGPIRDSA-NSMILESCOC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C

Targets

Q72874polP03366gag-pol

Transporters

P08183ABCB1P33527ABCC1Q9Y6L6SLCO1B1Q9NPD5SLCO1B3O95342ABCB11O94956SLCO2B1

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6TransportersSubstrate / inhibitor direction, not just membership

Listed above

2,021Drug interactionsStructured to mechanism, not free text

93Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose